TherapeuticsMD (TXMD) Misses Q3 EPS by 2c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/15/2026
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- Oil rises after US threatens indefinite blockade of Iran; set for weekly gains
- Are KOSPI and SOX in a bubble? Citi answers
- Could Intel return to the red-hot memory market after $20B raise and recent hire?
- BOJ eyeing September rate hike, faster pace of tightening, sources say
- S&P 500 ends lower as investors weigh data, Middle East tensions
- BofA's Hartnett explains why Wall Street is trading with 'no fear'
- SanDisk upgraded at JPMorgan after investor day; shares climb
- Micron: New Street upgrades to buy, says memory is no longer a cyclical story
TherapeuticsMD Expands Commercial and Business Development Leadership
November 3, 2016 4:08 PM EDT- Dawn Halkuff appointed Chief Commercial Officer -
- Yulii Bogatyrenko appointed Senior Vice President of Business Development -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced two new strategic hires: Dawn Halkuff as Chief Commercial Officer and Yulii Bogatyrenko as Senior Vice President of Business Development. Both executives bring womens health experience and relevant skills to the company in advance of the potential launch of its first bio-identical hormone... More
TherapeuticsMD Announces Third Quarter 2016 Financial Results
November 3, 2016 4:06 PM EDT- Topline phase 3 data for TX-001HR Replenish Trial on track for fourth quarter of 2016 -
- TX-004HR PDUFA target action date of May 7, 2017 -
BOCA RATON, Fla.--(BUSINESS WIRE)-- TherapeuticsMD, Inc. (NYSE MKT: TXMD), an innovative womens healthcare company, today announced its third quarter financial results for the quarter ended September 30, 2016.
Third Quarter and Recent Developments
Announced acceptance of a New Drug Application (NDA) by the U.S. Food and Drug Administration (FDA) for TX-004HR (conditionally-approved trade name... More